Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Review Article

MicroRNAs for Diagnosis and Treatment of Colorectal Cancer

Author(s): Haitao Mei and Yugang Wen*

Volume 21 , Issue 1 , 2021

Published on: 18 August, 2020

Page: [47 - 55] Pages: 9

DOI: 10.2174/1871530320999200818134339

Price: $65

Abstract

Colorectal cancer (CRC) is the third most common cancer worldwide, with high morbidity and mortality rates. The diagnosis and treatment of CRC have the most significant value for disease- free survival. Early diagnosis and early surgical resection are generally considered to be the most effective ways to reduce CRC mortality. In the past few years, many researchers have focused on the role of microRNAs in different tumors, making the functions of microRNAs gradually clear. The present study reviews the role of microRNAs in the diagnosis and treatment of colorectal cancer. Compared with the usual diagnosis methods and biomarker, circulating microRNAs can be promising new effective biomarkers for CRC diagnosis and treatment.

Keywords: CRC, diagnosis and treatment, liquid biopsy, miRNA, combined-biomarkers testing, tumorigenesis.

Graphical Abstract
[1]
Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics, 2012. CA Cancer J. Clin., 2015, 65(2), 87-108.
[http://dx.doi.org/10.3322/caac.21262] [PMID: 25651787]
[2]
Andrieu, N.; Launoy, G.; Guillois, R.; Ory-Paoletti, C.; Gignoux, M. Familial relative risk of colorectal cancer: A population-based study. Eur. J. Cancer, 2003, 39(13), 1904-1911.
[http://dx.doi.org/10.1016/S0959-8049(03)00420-9] [PMID: 12932670]
[3]
Zhu, J.; Tan, Z.; Hollis-Hansen, K.; Zhang, Y.; Yu, C.; Li, Y. Epidemiological trends in colorectal cancer in China: An ecological study. Dig. Dis. Sci., 2017, 62(1), 235-243.
[http://dx.doi.org/10.1007/s10620-016-4362-4] [PMID: 27796769]
[4]
Baxter, N.N.; Warren, J.L.; Barrett, M.J.; Stukel, T.A.; Doria-Rose, V.P. Association between colonoscopy and colorectal cancer mortality in a US cohort according to site of cancer and colonoscopist specialty. J. Clin. Oncol., 2012, 30(21), 2664-2669.
[http://dx.doi.org/10.1200/JCO.2011.40.4772] [PMID: 22689809]
[5]
Chen, C.Z.; Li, L.; Lodish, H.F.; Bartel, D.P. MicroRNAs modulate hematopoietic lineage differentiation. Science, 2004, 303(5654), 83-86.
[http://dx.doi.org/10.1126/science.1091903] [PMID: 14657504]
[6]
Brennecke, J.; Hipfner, D.R.; Stark, A.; Russell, R.B.; Cohen, S.M. bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell, 2003, 113(1), 25-36.
[http://dx.doi.org/10.1016/S0092-8674(03)00231-9] [PMID: 12679032]
[7]
Ghosh, R.; Singh, L.C.; Shohet, J.M.; Gunaratne, P.H. A gold nanoparticle platform for the delivery of functional microRNAs into cancer cells. Biomaterials, 2013, 34(3), 807-816.
[http://dx.doi.org/10.1016/j.biomaterials.2012.10.023] [PMID: 23111335]
[8]
Kota, J.; Chivukula, R.R.; O’Donnell, K.A.; Wentzel, E.A.; Montgomery, C.L.; Hwang, H.W.; Chang, T.C.; Vivekanandan, P.; Torbenson, M.; Clark, K.R.; Mendell, J.R.; Mendell, J.T. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell, 2009, 137(6), 1005-1017.
[http://dx.doi.org/10.1016/j.cell.2009.04.021] [PMID: 19524505]
[9]
Nishimura, J.; Handa, R.; Yamamoto, H.; Tanaka, F.; Shibata, K.; Mimori, K.; Takemasa, I.; Mizushima, T.; Ikeda, M.; Sekimoto, M.; Ishii, H.; Doki, Y.; Mori, M. microRNA-181a is associated with poor prognosis of colorectal cancer. Oncol. Rep., 2012, 28(6), 2221-2226.
[http://dx.doi.org/10.3892/or.2012.2059] [PMID: 23023298]
[10]
Ota, T.; Doi, K.; Fujimoto, T.; Tanaka, Y.; Ogawa, M.; Matsuzaki, H.; Kuroki, M.; Miyamoto, S.; Shirasawa, S.; Tsunoda, T. KRAS up-regulates the expression of miR-181a, miR-200c and miR-210 in a three-dimensional-specific manner in DLD-1 colorectal cancer cells. Anticancer Res., 2012, 32(6), 2271-2275.
[PMID: 22641662]
[11]
Croce, C.M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet., 2009, 10(10), 704-714.
[http://dx.doi.org/10.1038/nrg2634] [PMID: 19763153]
[12]
Kumar, M.S.; Lu, J.; Mercer, K.L.; Golub, T.R.; Jacks, T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat. Genet., 2007, 39(5), 673-677.
[http://dx.doi.org/10.1038/ng2003] [PMID: 17401365]
[13]
Calin, G.A.; Dumitru, C.D.; Shimizu, M.; Bichi, R.; Zupo, S.; Noch, E.; Aldler, H.; Rattan, S.; Keating, M.; Rai, K.; Rassenti, L.; Kipps, T.; Negrini, M.; Bullrich, F.; Croce, C.M. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA, 2002, 99(24), 15524-15529.
[http://dx.doi.org/10.1073/pnas.242606799] [PMID: 12434020]
[14]
Esquela-Kerscher, A.; Slack, F.J. Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer, 2006, 6(4), 259-269.
[http://dx.doi.org/10.1038/nrc1840] [PMID: 16557279]
[15]
Winawer, S.J. The history of colorectal cancer screening: A personal perspective. Dig. Dis. Sci., 2015, 60(3), 596-608.
[http://dx.doi.org/10.1007/s10620-014-3466-y] [PMID: 25599958]
[16]
Rex, D.K.; Johnson, D.A.; Anderson, J.C.; Schoenfeld, P.S.; Burke, C.A.; Inadomi, J.M. American College of Gastroenterology. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am. J. Gastroenterol., 2009, 104(3), 739-750.
[http://dx.doi.org/10.1038/ajg.2009.104] [PMID: 19240699]
[17]
Pox, C.P. Controversies in colorectal cancer screening. Digestion, 2014, 89(4), 274-281.
[http://dx.doi.org/10.1159/000363287] [PMID: 25034478]
[18]
Shaukat, A.; Mongin, S.J.; Geisser, M.S.; Lederle, F.A.; Bond, J.H.; Mandel, J.S.; Church, T.R. Long-term mortality after screening for colorectal cancer. N. Engl. J. Med., 2013, 369(12), 1106-1114.
[http://dx.doi.org/10.1056/NEJMoa1300720] [PMID: 24047060]
[19]
Normanno, N.; Cervantes, A.; Ciardiello, F.; De Luca, A.; Pinto, C. The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios. Cancer Treat. Rev., 2018, 70, 1-8.
[http://dx.doi.org/10.1016/j.ctrv.2018.07.007] [PMID: 30053724]
[20]
Schwarzenbach, H.; Nishida, N.; Calin, G.A.; Pantel, K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat. Rev. Clin. Oncol., 2014, 11(3), 145-156.
[http://dx.doi.org/10.1038/nrclinonc.2014.5] [PMID: 24492836]
[21]
Byron, S.A.; Van Keuren-Jensen, K.R.; Engelthaler, D.M.; Carpten, J.D.; Craig, D.W. Translating RNA sequencing into clinical diagnostics: opportunities and challenges. Nat. Rev. Genet., 2016, 17(5), 257-271.
[http://dx.doi.org/10.1038/nrg.2016.10] [PMID: 26996076]
[22]
Zanutto, S.; Ciniselli, C.M.; Belfiore, A.; Lecchi, M.; Masci, E.; Delconte, G.; Primignani, M.; Tosetti, G.; Dal Fante, M.; Fazzini, L.; Airoldi, A.; Vangeli, M.; Turpini, F.; Rubis Passoni, G.G.; Viaggi, P.; Arena, M.; Motta, R.I.O.; Cantù, A.M.; Crosta, C.; De Roberto, G.; Iannuzzi, F.; Cassinotti, A.; Dall’Olio, V.; Tizzoni, L.; Sozzi, G.; Meroni, E.; Bisanti, L.; Pierotti, M.A.; Verderio, P.; Gariboldi, M. Plasma miRNA-based signatures in CRC screening programs. Int. J. Cancer, 2020, 146(4), 1164-1173.
[http://dx.doi.org/10.1002/ijc.32573] [PMID: 31304978]
[23]
Afshar, S.; Afshar, S.; Warden, E.; Manochehri, H.; Saidijam, M. Application of artificial neural network in miRNA biomarker selection and precise diagnosis of colorectal cancer. Iran. Biomed. J., 2019, 23(3), 175-183.
[http://dx.doi.org/10.29252/ibj.23.3.175] [PMID: 30056689]
[24]
Qu, A.; Yang, Y.; Zhang, X.; Wang, W.; Liu, Y.; Zheng, G.; Du, L.; Wang, C. Development of a preoperative prediction nomogram for lymph node metastasis in colorectal cancer based on a novel serum miRNA signature and CT scans. EBioMedicine, 2018, 37, 125-133.
[http://dx.doi.org/10.1016/j.ebiom.2018.09.052] [PMID: 30314890]
[25]
Mitchell, P.S.; Parkin, R.K.; Kroh, E.M.; Fritz, B.R.; Wyman, S.K.; Pogosova-Agadjanyan, E.L.; Peterson, A.; Noteboom, J.; O’Briant, K.C.; Allen, A.; Lin, D.W.; Urban, N.; Drescher, C.W.; Knudsen, B.S.; Stirewalt, D.L.; Gentleman, R.; Vessella, R.L.; Nelson, P.S.; Martin, D.B.; Tewari, M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA, 2008, 105(30), 10513-10518.
[http://dx.doi.org/10.1073/pnas.0804549105] [PMID: 18663219]
[26]
Slaby, O.; Svoboda, M.; Michalek, J.; Vyzula, R. MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol. Cancer, 2009, 8, 102.
[http://dx.doi.org/10.1186/1476-4598-8-102] [PMID: 19912656]
[27]
Kim, V.N. MicroRNA biogenesis: coordinated cropping and dicing. Nat. Rev. Mol. Cell Biol., 2005, 6(5), 376-385.
[http://dx.doi.org/10.1038/nrm1644] [PMID: 15852042]
[28]
Bartel, D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell, 2004, 116(2), 281-297.
[http://dx.doi.org/10.1016/S0092-8674(04)00045-5] [PMID: 14744438]
[29]
Lee, Y.; Kim, M.; Han, J.; Yeom, K.H.; Lee, S.; Baek, S.H.; Kim, V.N. MicroRNA genes are transcribed by RNA polymerase II. EMBO J., 2004, 23(20), 4051-4060.
[http://dx.doi.org/10.1038/sj.emboj.7600385] [PMID: 15372072]
[30]
Borchert, G.M.; Lanier, W.; Davidson, B.L. RNA polymerase III transcribes human microRNAs. Nat. Struct. Mol. Biol., 2006, 13(12), 1097-1101.
[http://dx.doi.org/10.1038/nsmb1167] [PMID: 17099701]
[31]
Rossi, S.; Kopetz, S.; Davuluri, R.; Hamilton, S.R.; Calin, G.A. MicroRNAs, ultraconserved genes and colorectal cancers. Int. J. Biochem. Cell Biol., 2010, 42(8), 1291-1297.
[http://dx.doi.org/10.1016/j.biocel.2009.05.018] [PMID: 19497386]
[32]
Lu, Y.; Zhao, X.; Liu, Q.; Li, C.; Graves-Deal, R.; Cao, Z.; Singh, B.; Franklin, J.L.; Wang, J.; Hu, H.; Wei, T.; Yang, M.; Yeatman, T.J.; Lee, E.; Saito-Diaz, K.; Hinger, S.; Patton, J.G.; Chung, C.H.; Emmrich, S.; Klusmann, J.H.; Fan, D.; Coffey, R.J. lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-catenin signaling. Nat. Med., 2017, 23(11), 1331-1341.
[http://dx.doi.org/10.1038/nm.4424] [PMID: 29035371]
[33]
Alam, K.J.; Mo, J.S.; Han, S.H.; Park, W.C.; Kim, H.S.; Yun, K.J.; Chae, S.C. MicroRNA 375 regulates proliferation and migration of colon cancer cells by suppressing the CTGF-EGFR signaling pathway. Int. J. Cancer, 2017, 141(8), 1614-1629.
[http://dx.doi.org/10.1002/ijc.30861] [PMID: 28670764]
[34]
Mármol, I.; Sánchez-de-Diego, C.; Pradilla Dieste, A.; Cerrada, E.; Rodriguez Yoldi, M.J. Colorectal carcinoma: A general overview and future perspectives in colorectal cancer. Int. J. Mol. Sci., 2017, 18(1)E197
[http://dx.doi.org/10.3390/ijms18010197] [PMID: 28106826]
[35]
Li, H.; Rokavec, M.; Jiang, L.; Horst, D.; Hermeking, H. Antagonistic effects of p53 and HIF1A on microRNA-34a regulation of PPP1R11 and STAT3 and hypoxia-induced epithelial to mesenchymal transition in colorectal cancer cells. Gastroenterology, 2017, 153(2), 505-520.
[http://dx.doi.org/10.1053/j.gastro.2017.04.017] [PMID: 28435028]
[36]
Weber, J.A.; Baxter, D.H.; Zhang, S.; Huang, D.Y.; Huang, K.H.; Lee, M.J.; Galas, D.J.; Wang, K. The microRNA spectrum in 12 body fluids. Clin. Chem., 2010, 56(11), 1733-1741.
[http://dx.doi.org/10.1373/clinchem.2010.147405] [PMID: 20847327]
[37]
Liu, J.; Li, H.; Zheng, B.; Sun, L.; Yuan, Y.; Xing, C. Competitive endogenous RNA (ceRNA) regulation network of lncRNA-miRNA-mRNA in colorectal carcinogenesis. Dig. Dis. Sci., 2019, 64(7), 1868-1877.
[http://dx.doi.org/10.1007/s10620-019-05506-9] [PMID: 30734239]
[38]
Boon, R.A.; Vickers, K.C. Intercellular transport of microRNAs. Arterioscler. Thromb. Vasc. Biol., 2013, 33(2), 186-192.
[http://dx.doi.org/10.1161/ATVBAHA.112.300139] [PMID: 23325475]
[39]
Gorbea, C.; Mosbruger, T.; Cazalla, D. A viral Sm-class RNA base-pairs with mRNAs and recruits microRNAs to inhibit apoptosis. Nature, 2017, 550(7675), 275-279.
[http://dx.doi.org/10.1038/nature24034] [PMID: 28976967]
[40]
Song, J.H.; Meltzer, S.J. MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers. Gastroenterology, 2012, 143(1), 35-47.e2.
[http://dx.doi.org/10.1053/j.gastro.2012.05.003] [PMID: 22580099]
[41]
Bayraktar, R.; Van Roosbroeck, K.; Calin, G.A. Cell-to-cell communication: microRNAs as hormones. Mol. Oncol., 2017, 11(12), 1673-1686.
[http://dx.doi.org/10.1002/1878-0261.12144] [PMID: 29024380]
[42]
Zhang, Y.; Liu, D.; Chen, X.; Li, J.; Li, L.; Bian, Z.; Sun, F.; Lu, J.; Yin, Y.; Cai, X.; Sun, Q.; Wang, K.; Ba, Y.; Wang, Q.; Wang, D.; Yang, J.; Liu, P.; Xu, T.; Yan, Q.; Zhang, J.; Zen, K.; Zhang, C.Y. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol. Cell, 2010, 39(1), 133-144.
[http://dx.doi.org/10.1016/j.molcel.2010.06.010] [PMID: 20603081]
[43]
Cuyle, P.J.; Prenen, H. Current and future biomarkers in the treatment of colorectal cancer. Acta Clin. Belg., 2017, 72(2), 103-115.
[http://dx.doi.org/10.1080/17843286.2016.1262996] [PMID: 27917697]
[44]
Monteleone, N.J.; Moore, A.E.; Iacona, J.R.; Lutz, C.S.; Dixon, D.A. miR-21-mediated regulation of 15-hydroxyprostaglandin dehydrogenase in colon cancer. Sci. Rep., 2019, 9(1), 5405.
[http://dx.doi.org/10.1038/s41598-019-41862-2] [PMID: 30931980]
[45]
Carter, J.V.; Galbraith, N.J.; Yang, D.; Burton, J.F.; Walker, S.P.; Galandiuk, S. Blood-based microRNAs as biomarkers for the diagnosis of colorectal cancer: A systematic review and meta-analysis. Br. J. Cancer, 2017, 116(6), 762-774.
[http://dx.doi.org/10.1038/bjc.2017.12] [PMID: 28152545]
[46]
Yu, W.; Wang, Z.; Shen, L.I.; Wei, Q. Circulating microRNA-21 as a potential diagnostic marker for colorectal cancer: A meta-analysis. Mol. Clin. Oncol., 2016, 4(2), 237-244.
[http://dx.doi.org/10.3892/mco.2015.702] [PMID: 26893868]
[47]
Guo, X.; Lv, X.; Lv, X.; Ma, Y.; Chen, L.; Chen, Y. Circulating miR-21 serves as a serum biomarker for hepatocellular carcinoma and correlated with distant metastasis. Oncotarget, 2017, 8(27), 44050-44058.
[http://dx.doi.org/10.18632/oncotarget.17211] [PMID: 28477010]
[48]
Wu, Y.; Song, Y.; Xiong, Y.; Wang, X.; Xu, K.; Han, B.; Bai, Y.; Li, L.; Zhang, Y.; Zhou, L. MicroRNA-21 (Mir-21) promotes cell growth and invasion by repressing tumor suppressor PTEN in colorectal cancer. Cell. Physiol. Biochem., 2017, 43(3), 945-958.
[http://dx.doi.org/10.1159/000481648] [PMID: 28957811]
[49]
Igder, S.; Mohammadiasl, J.; Mokarram, P. Altered miR-21, miRNA-148a expression in relation to KRAS mutation status as indicator of adenoma-carcinoma transitional pattern in colorectal adenoma and carcinoma lesions. Biochem. Genet., 2019, 57(6), 767-780.
[http://dx.doi.org/10.1007/s10528-019-09918-0] [PMID: 30997628]
[50]
Sabry, D.; El-Deek, S.E.M.; Maher, M.; El-Baz, M.A.H.; El-Bader, H.M.; Amer, E.; Hassan, E.A.; Fathy, W.; El-Deek, H.E.M. Role of miRNA-210, miRNA-21 and miRNA-126 as diagnostic biomarkers in colorectal carcinoma: Impact of HIF-1α-VEGF signaling pathway. Mol. Cell. Biochem., 2019, 454(1-2), 177-189.
[http://dx.doi.org/10.1007/s11010-018-3462-1] [PMID: 30357530]
[51]
Motoyama, K.; Inoue, H.; Takatsuno, Y.; Tanaka, F.; Mimori, K.; Uetake, H.; Sugihara, K.; Mori, M. Over- and under-expressed microRNAs in human colorectal cancer. Int. J. Oncol., 2009, 34(4), 1069-1075.
[PMID: 19287964]
[52]
Wang, Y.X.; Zhang, X.Y.; Zhang, B.F.; Yang, C.Q.; Chen, X.M.; Gao, H.J. Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. J. Dig. Dis., 2010, 11(1), 50-54.
[http://dx.doi.org/10.1111/j.1751-2980.2009.00413.x] [PMID: 20132431]
[53]
Huang, G.; Wu, X.; Li, S.; Xu, X.; Zhu, H.; Chen, X. The long noncoding RNA CASC2 functions as a competing endogenous RNA by sponging miR-18a in colorectal cancer. Sci. Rep., 2016, 6, 26524.
[http://dx.doi.org/10.1038/srep26524] [PMID: 27198161]
[54]
Wu, C.W.; Dong, Y.J.; Liang, Q.Y.; He, X.Q.; Ng, S.S.; Chan, F.K.; Sung, J.J.; Yu, J. MicroRNA-18a attenuates DNA damage repair through suppressing the expression of ataxia telangiectasia mutated in colorectal cancer. PLoS One, 2013, 8(2), e57036.
[http://dx.doi.org/10.1371/journal.pone.0057036] [PMID: 23437304]
[55]
Brunet Vega, A.; Pericay, C.; Moya, I.; Ferrer, A.; Dotor, E.; Pisa, A.; Casalots, À.; Serra-Aracil, X.; Oliva, J.C.; Ruiz, A.; Saigí, E. microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers. Oncol. Rep., 2013, 30(1), 320-326.
[http://dx.doi.org/10.3892/or.2013.2475] [PMID: 23673725]
[56]
Luo, X.; Stock, C.; Burwinkel, B.; Brenner, H. Identification and evaluation of plasma microRNAs for early detection of colorectal cancer. PLoS One, 2013, 8(5), e62880.
[http://dx.doi.org/10.1371/journal.pone.0062880] [PMID: 23690963]
[57]
Zhang, G.J.; Zhou, T.; Liu, Z.L.; Tian, H.P.; Xia, S.S. Plasma miR-200c and miR-18a as potential biomarkers for the detection of colorectal carcinoma. Mol. Clin. Oncol., 2013, 1(2), 379-384.
[http://dx.doi.org/10.3892/mco.2013.61] [PMID: 24649179]
[58]
Tang, W.; Zhu, Y.; Gao, J.; Fu, J.; Liu, C.; Liu, Y.; Song, C.; Zhu, S.; Leng, Y.; Wang, G.; Chen, W.; Du, P.; Huang, S.; Zhou, X.; Kang, J.; Cui, L. MicroRNA-29a promotes colorectal cancer metastasis by regulating matrix metalloproteinase 2 and E-cadherin via KLF4. Br. J. Cancer, 2014, 110(2), 450-458.
[http://dx.doi.org/10.1038/bjc.2013.724] [PMID: 24281002]
[59]
Wang, J.; Xu, J.; Fu, J.; Yuan, D.; Guo, F.; Zhou, C.; Shao, C. MiR-29a Regulates Radiosensitivity in Human Intestinal Cells by Targeting PTEN Gene. Radiat. Res., 2016, 186(3), 292-301.
[http://dx.doi.org/10.1667/RR14428.1] [PMID: 27548517]
[60]
Huang, Z.; Huang, D.; Ni, S.; Peng, Z.; Sheng, W.; Du, X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int. J. Cancer, 2010, 127(1), 118-126.
[http://dx.doi.org/10.1002/ijc.25007] [PMID: 19876917]
[61]
Zhi, M.L.; Liu, Z.J.; Yi, X.Y.; Zhang, L.J.; Bao, Y.X. Diagnostic performance of microRNA-29a for colorectal cancer: A meta-analysis. Genet. Mol. Res., 2015, 14(4), 18018-18025.
[http://dx.doi.org/10.4238/2015.December.22.28] [PMID: 26782449]
[62]
Ramzy, I.; Hasaballah, M.; Marzaban, R.; Shaker, O.; Soliman, Z.A. Evaluation of microRNAs-29a, 92a and 145 in colorectal carcinoma as candidate diagnostic markers: An Egyptian pilot study. Clin. Res. Hepatol. Gastroenterol., 2015, 39(4), 508-515.
[http://dx.doi.org/10.1016/j.clinre.2014.12.008] [PMID: 25736690]
[63]
Hao, H.; Xia, G.; Wang, C.; Zhong, F.; Liu, L.; Zhang, D. miR-106a suppresses tumor cells death in colorectal cancer through targeting ATG7. Med. Mol. Morphol., 2017, 50(2), 76-85.
[http://dx.doi.org/10.1007/s00795-016-0150-7] [PMID: 27981410]
[64]
Feng, B.; Dong, T.T.; Wang, L.L.; Zhou, H.M.; Zhao, H.C.; Dong, F.; Zheng, M.H. Colorectal cancer migration and invasion initiated by microRNA-106a. PLoS One, 2012, 7(8), e43452.
[http://dx.doi.org/10.1371/journal.pone.0043452] [PMID: 22912877]
[65]
Shaker, O.G.; Ali, M.A.; Ahmed, T.I.; Zaki, O.M.; Ali, D.Y.; Hassan, E.A.; Hemeda, N.F.; AbdelHafez, M.N. Association between LINC00657 and miR-106a serum expression levels and susceptibility to colorectal cancer, adenomatous polyposis, and ulcerative colitis in Egyptian population. IUBMB Life, 2019, 71(9), 1322-1335.
[http://dx.doi.org/10.1002/iub.2039] [PMID: 30927333]
[66]
Kozomara, A.; Griffiths-Jones, S. miRBase: Annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res., 2014, 42(Database issue), D68-D73.
[http://dx.doi.org/10.1093/nar/gkt1181] [PMID: 24275495]
[67]
Eslamizadeh, S.; Heidari, M.; Agah, S.; Faghihloo, E.; Ghazi, H.; Mirzaei, A.; Akbari, A. The role of microRNA signature as diagnostic biomarkers in different clinical stages of colorectal cancer. Cell J., 2018, 20(2), 220-230.
[PMID: 29633600]
[68]
Chivukula, R.R.; Shi, G.; Acharya, A.; Mills, E.W.; Zeitels, L.R.; Anandam, J.L.; Abdelnaby, A.A.; Balch, G.C.; Mansour, J.C.; Yopp, A.C.; Maitra, A.; Mendell, J.T. An essential mesenchymal function for miR-143/145 in intestinal epithelial regeneration. Cell, 2014, 157(5), 1104-1116.
[http://dx.doi.org/10.1016/j.cell.2014.03.055] [PMID: 24855947]
[69]
Kent, O.A.; McCall, M.N.; Cornish, T.C.; Halushka, M.K. Lessons from miR-143/145: The importance of cell-type localization of miRNAs. Nucleic Acids Res., 2014, 42(12), 7528-7538.
[http://dx.doi.org/10.1093/nar/gku461] [PMID: 24875473]
[70]
Xu, L.; Zhang, Y.; Tang, J.; Wang, P.; Li, L.; Yan, X.; Zheng, X.; Ren, S.; Zhang, M.; Xu, M. The prognostic value and regulatory mechanisms of microRNA-145 in various tumors: A systematic review and meta-analysis of 50 studies. Cancer Epidemiol. Biomarkers Prev., 2019, 28(5), 867-881.
[http://dx.doi.org/10.1158/1055-9965.EPI-18-0570] [PMID: 30602498]
[71]
Luo, X.; Wu, Y.; Ji, M.; Zhang, S. Combined plasma microRNA and fecal occult blood tests in early detection of colorectal cancer. Clin. Lab., 2019, 65(5)
[http://dx.doi.org/10.7754/Clin.Lab.2018.180926] [PMID: 31115212]
[72]
Liu, Q.; Yang, W.; Luo, Y.; Hu, S.; Zhu, L. Correlation between miR-21 and miR-145 and the incidence and prognosis of colorectal cancer. J. BUON, 2018, 23(1), 29-35.
[PMID: 29552756]
[73]
Wang, Q.; Huang, Z.; Ni, S.; Xiao, X.; Xu, Q.; Wang, L.; Huang, D.; Tan, C.; Sheng, W.; Du, X. Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer. PLoS One, 2012, 7(9), e44398.
[http://dx.doi.org/10.1371/journal.pone.0044398] [PMID: 22970209]
[74]
Hofsli, E.; Sjursen, W.; Prestvik, W.S.; Johansen, J.; Rye, M.; Tranø, G.; Wasmuth, H.H.; Hatlevoll, I.; Thommesen, L. Identification of serum microRNA profiles in colon cancer. Br. J. Cancer, 2013, 108(8), 1712-1719.
[http://dx.doi.org/10.1038/bjc.2013.121] [PMID: 23558896]
[75]
Tamai, K.; Tanaka, N.; Nakano, T.; Kakazu, E.; Kondo, Y.; Inoue, J.; Shiina, M.; Fukushima, K.; Hoshino, T.; Sano, K.; Ueno, Y.; Shimosegawa, T.; Sugamura, K. Exosome secretion of dendritic cells is regulated by Hrs, an ESCRT-0 protein. Biochem. Biophys. Res. Commun., 2010, 399(3), 384-390.
[http://dx.doi.org/10.1016/j.bbrc.2010.07.083] [PMID: 20673754]
[76]
Tran, N. Cancer Exosomes as miRNA Factories. Trends Cancer, 2016, 2(7), 329-331.
[http://dx.doi.org/10.1016/j.trecan.2016.05.008] [PMID: 28741535]
[77]
Ohshima, K.; Inoue, K.; Fujiwara, A.; Hatakeyama, K.; Kanto, K.; Watanabe, Y.; Muramatsu, K.; Fukuda, Y.; Ogura, S.; Yamaguchi, K.; Mochizuki, T. Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. PLoS One, 2010, 5(10), e13247.
[http://dx.doi.org/10.1371/journal.pone.0013247] [PMID: 20949044]
[78]
Ogata-Kawata, H.; Izumiya, M.; Kurioka, D.; Honma, Y.; Yamada, Y.; Furuta, K.; Gunji, T.; Ohta, H.; Okamoto, H.; Sonoda, H.; Watanabe, M.; Nakagama, H.; Yokota, J.; Kohno, T.; Tsuchiya, N. Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One, 2014, 9(4), e92921.
[http://dx.doi.org/10.1371/journal.pone.0092921] [PMID: 24705249]
[79]
Sequeiros, T.; Rigau, M.; Chiva, C.; Montes, M.; Garcia-Grau, I.; Garcia, M.; Diaz, S.; Celma, A.; Bijnsdorp, I.; Campos, A.; Di Mauro, P.; Borrós, S.; Reventós, J.; Doll, A.; Paciucci, R.; Pegtel, M.; de Torres, I.; Sabidó, E.; Morote, J.; Olivan, M. Targeted proteomics in urinary extracellular vesicles identifies biomarkers for diagnosis and prognosis of prostate cancer. Oncotarget, 2017, 8(3), 4960-4976.
[http://dx.doi.org/10.18632/oncotarget.13634] [PMID: 27903962]
[80]
Martinez-Garcia, E.; Lesur, A.; Devis, L.; Cabrera, S.; Matias-Guiu, X.; Hirschfeld, M.; Asberger, J.; van Oostrum, J.; Casares de Cal, M.L.A.; Gómez-Tato, A.; Reventos, J.; Domon, B.; Colas, E.; Gil-Moreno, A. Targeted Proteomics Identifies Proteomic Signatures in Liquid Biopsies of the Endometrium to Diagnose Endometrial Cancer and Assist in the Prediction of the Optimal Surgical Treatment. Clin. Cancer Res., 2017, 23(21), 6458-6467.
[http://dx.doi.org/10.1158/1078-0432.CCR-17-0474] [PMID: 28790116]
[81]
Roman-Canal, B.; Tarragona, J.; Moiola, C.P.; Gatius, S.; Bonnin, S.; Ruiz-Miró, M.; Sierra, J.E.; Rufas, M.; González, E.; Porcel, J.M.; Gil-Moreno, A.; Falcón-Pérez, J.M.; Ponomarenko, J.; Matias-Guiu, X.; Colas, E. EV-associated miRNAs from peritoneal lavage as potential diagnostic biomarkers in colorectal cancer. J. Transl. Med., 2019, 17(1), 208.
[http://dx.doi.org/10.1186/s12967-019-1954-8] [PMID: 31221189]
[82]
Dahan, L.; Sadok, A.; Formento, J.L.; Seitz, J.F.; Kovacic, H. Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines. Br. J. Pharmacol., 2009, 158(2), 610-620.
[http://dx.doi.org/10.1111/j.1476-5381.2009.00341.x] [PMID: 19732064]
[83]
Chen, G. Interpretation of the updates of NCCN 2017 version 1.0 guideline for colorectal cancer. Zhonghua Wei Chang Wai Ke Za Zhi, 2017, 20(1), 28-33.
[PMID: 28105616]
[84]
Goldstein, N.S.; Armin, M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer, 2001, 92(5), 1331-1346.
[http://dx.doi.org/10.1002/1097-0142(20010901)92:5<1331::AID-CNCR1455>3.0.CO;2-M] [PMID: 11571750]
[85]
Karapetis, C.S.; Khambata-Ford, S.; Jonker, D.J.; O’Callaghan, C.J.; Tu, D.; Tebbutt, N.C.; Simes, R.J.; Chalchal, H.; Shapiro, J.D.; Robitaille, S.; Price, T.J.; Shepherd, L.; Au, H.J.; Langer, C.; Moore, M.J.; Zalcberg, J.R. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med., 2008, 359(17), 1757-1765.
[http://dx.doi.org/10.1056/NEJMoa0804385] [PMID: 18946061]
[86]
Merlos-Suárez, A.; Barriga, F.M.; Jung, P.; Iglesias, M.; Céspedes, M.V.; Rossell, D.; Sevillano, M.; Hernando-Momblona, X.; da Silva-Diz, V.; Muñoz, P.; Clevers, H.; Sancho, E.; Mangues, R.; Batlle, E. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell, 2011, 8(5), 511-524.
[http://dx.doi.org/10.1016/j.stem.2011.02.020] [PMID: 21419747]
[87]
Zhang, B.; Pan, X.; Cobb, G.P.; Anderson, T.A. microRNAs as oncogenes and tumor suppressors. Dev. Biol., 2007, 302(1), 1-12.
[http://dx.doi.org/10.1016/j.ydbio.2006.08.028] [PMID: 16989803]
[88]
Liu, K.; Yao, H.; Wen, Y.; Zhao, H.; Zhou, N.; Lei, S.; Xiong, L. Functional role of a long non-coding RNA LIFR-AS1/miR-29a/TNFAIP3 axis in colorectal cancer resistance to pohotodynamic therapy. Biochim. Biophys. Acta Mol. Basis Dis., 2018, 1864(9 Pt B), 2871-2880.
[http://dx.doi.org/10.1016/j.bbadis.2018.05.020] [PMID: 29807108]
[89]
Moridikia, A.; Mirzaei, H.; Sahebkar, A.; Salimian, J. MicroRNAs: Potential candidates for diagnosis and treatment of colorectal cancer. J. Cell. Physiol., 2018, 233(2), 901-913.
[http://dx.doi.org/10.1002/jcp.25801] [PMID: 28092102]
[90]
Rothschild, S.I. microRNA therapies in cancer. Mol. Cell. Ther., 2014, 2, 7.
[http://dx.doi.org/10.1186/2052-8426-2-7] [PMID: 26056576]
[91]
Bouchie, A. First microRNA mimic enters clinic. Nat. Biotechnol., 2013, 31(7), 577.
[http://dx.doi.org/10.1038/nbt0713-577] [PMID: 23839128]
[92]
Chen, Y.; Gao, D.Y.; Huang, L. In vivo delivery of miRNAs for cancer therapy: Challenges and strategies. Adv. Drug Deliv. Rev., 2015, 81, 128-141.
[http://dx.doi.org/10.1016/j.addr.2014.05.009] [PMID: 24859533]
[93]
Kanaan, Z.; Roberts, H.; Eichenberger, M.R.; Billeter, A.; Ocheretner, G.; Pan, J.; Rai, S.N.; Jorden, J.; Williford, A.; Galandiuk, S. A plasma microRNA panel for detection of colorectal adenomas: a step toward more precise screening for colorectal cancer. Ann. Surg., 2013, 258(3), 400-408.
[http://dx.doi.org/10.1097/SLA.0b013e3182a15bcc] [PMID: 24022433]
[94]
Bartel, D.P.; Chen, C.Z. Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat. Rev. Genet., 2004, 5(5), 396-400.
[http://dx.doi.org/10.1038/nrg1328] [PMID: 15143321]

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy